Role for Streptococcal Collagen-Like Protein 1 in M1T1 Group A Streptococcus Resistance to Neutrophil Extracellular Traps

Simon Döhrmann, a Sabina Anik, a Joshua Olson, a Ericka L. Anderson, a Neelou Etesami, a Hyewon No, b Joshua Snipper, b Victor Nizet, a,c Cheryl Y. M. Okumura a,b

Department of Pediatrics, University of California, San Diego, La Jolla, California, USA a; Department of Biology, Occidental College, Los Angeles, California, USA b; Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California, USA c

Streptococcal collagen-like protein 1 (Scl-1) is one of the most highly expressed proteins in the invasive M1T1 serotype group A Streptococcus (GAS), a globally disseminated clone associated with higher risk of severe invasive infections. Previous studies using recombinant Scl-1 protein suggested a role in cell attachment and binding and inhibition of serum proteins. Here, we studied the contribution of Scl-1 to the virulence of the M1T1 clone in the physiological context of the live bacterium by generating an isogenic strain lacking the scl-1 gene. Upon subcutaneous infection in mice, wild-type bacteria induced larger lesions than the Δscl mutant. However, loss of Scl-1 did not alter bacterial adherence to or invasion of skin keratinocytes. We found instead that Scl-1 plays a critical role in GAS resistance to human and murine phagocytic cells, allowing the bacteria to persist at the site of infection. Phenotypic analyses demonstrated that Scl-1 mediates bacterial survival in neutrophil extracellular traps (NETs) and protects GAS from antimicrobial peptides found within the NETs. Additionally, Scl-1 interferes with myeloperoxidase (MPO) release, a prerequisite for NET production, thereby suppressing NET formation. We conclude that Scl-1 is a virulence determinant in the M1T1 GAS clone, allowing GAS to subvert innate immune functions that are critical in clearing bacterial infections.

G
group A Streptococcus (GAS) (Streptococcus pyogenes) is among the top 10 human pathogens worldwide and is responsible for considerable infection-associated morbidity and mortality (1). GAS manifests in a broad array of diseases ranging from self-limiting infections, such as impetigo and pharyngitis, to life-threatening conditions, such as necrotizing fasciitis and toxic shock syndrome (2). Overall, GAS annually causes about 700 million infections, including 650,000 severe invasive infections (1), yet no commercial vaccines to protect against GAS disease are currently available.

Infectious disease outcome is determined in large part by the functions of the host innate immune response. In the setting of acute bacterial infection, the first innate immune cells recruited to the site of infection are neutrophils, which employ three basic mechanisms to clear the pathogen: phagocytosis, exposure to antimicrobial content stored in granules, and extracellular killing via phagocyte extracellular traps, particularly neutrophil extracellular traps (NETs) (3). To combat these defenses, GAS has evolved several strategies to evade and counteract the innate phagocyte immune response (2). A significant portion of the global burden of invasive GAS disease is attributable to the prevalent M1T1 clone (4, 5), which encodes multiple immune evasion genes, including factors that impede neutrophil recruitment, limit phagocytosis (6, 7), resist antimicrobial peptides (8, 9), and degrade NETs (10, 11). These multiple immune evasion mechanisms may allow GAS to resist the innate immune defenses of the host and allow the bacteria to produce systemic infections, including infections in previously healthy individuals.

Among known and potential virulence factors of GAS, the gene encoding streptococcal collagen-like 1 protein (Scl-1, also denoted ScIa) has been shown to be one of the most highly upregulated genes in strains causing invasive infections (12) and in whole-blood infections (13). Scl-1 encodes a surface protein bearing a collagen-like domain that is conserved among GAS strains and a hypervariable N-terminal domain (14, 15). In other, less virulent GAS serotype strains, Scl-1 has been shown to participate in biofilm formation (16, 17), attachment to extracellular matrix proteins (18), and attachment to lung epithelial cells (15, 19, 20) but not pharyngeal cells (14). Studies using recombinant Scl-1 have shown that the protein, via its serotype-hypervariable N terminus, can bind a variety of host proteins, including serum lipoproteins (21, 22), integrins (23, 24), the complement inhibitors FH and FH-related protein 1 (25, 26), and the thrombin-activatable fibrinolysis inhibitor (27). While Scl-1 proteins of different GAS serotypes bind a variety of host proteins, the results suggest a common role for Scl-1 in perturbing the functions of the innate immune system.

Despite numerous detailed studies using recombinant Scl-1 protein, very few studies have examined the role of Scl-1 at physiological expression levels and in the context of the living pathogen. Of those studies using isogenic mutants and various infection models, differences in virulence between strains possessing and lacking Scl-1 have been relatively mild (14, 15, 17, 18), which may be in part due to the overall moderate virulence characteristics of the bacterial strains studied. The current work explores the importance of this protein in the context of a highly virulent M1T1 clone. Our analysis reveals that Scl-1 plays an important role in

Received 11 April 2014 Returned for modification 9 May 2014
Accepted 1 July 2014
Published ahead of print 14 July 2014

Editor: L. Proffi
Address correspondence to Victor Nizet, vnizet@ucsd.edu, or Cheryl Y. M. Okumura, okumura@oxy.edu.
Supplemental material for this article may be found at http://dx.doi.org/10.1128/IAI.01921-14.

Copyright © 2014, American Society for Microbiology. All Rights Reserved.
doi:10.1128/IAI.01921-14

Published January 2014 Volume 82 Number 10 Infection and Immunity p. 4011–4020 iai.asm.org 4011
MATERIALS AND METHODS

Cell culture. THP-1 (ATCC TIB-202), HaCaT (28), and J774 (ATCC TIB-67) cells were maintained in RPMI or Dulbecco modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and penicillin-streptomycin (Invitrogen). Neutrophils were isolated from healthy donors (with use and procedures approved by the University of California San Diego Human Research Protections Program) using the PolymorphPrep kit (Fresenius Kabi) as previously described (29).

Bacterial strains and mutant construction. Wild-type (WT) GAS strain M1T1 5448 was originally isolated from a patient with necrotizing fasciitis and toxic shock syndrome (30) and was cultivated in Todd-He-g/ml penicillin plus 100 

The bacterial load in the lesions was determined by enumeration of lesion multiplicity of infection (MOI) of 10 bacteria to 1 cell. Plates were centrifuged 1 day prior to the assay. Log-phase bacteria were used to infect cells at a MOI of 10 with the nonopsonized log-phase WT or Δscl mutant strain transformed with a plasmid encoding GFP. Cells were incubated for 20 min in the presence or absence of 10 μg/ml clyt D and then incubated for 10 min with 100 U/ml penicillin and 100 μg/ml streptomycin to kill extracellular bacteria. Cells were washed three times with PBS, fixed with 4% paraformaldehyde, and analyzed by flow cytometry. Neutrophils were gated by side and forward scatter, and the fluorescence intensity was measured for a total of 10,000 cells. Uninfected PMNs were used as a negative control. Flow cytometry data were analyzed with FlowJo v. 9.4.10 (Tree Star, Inc.). To visualize extracellular bacteria by fluorescence microscopy, nonpermeabilized cells were incubated with 0.01 mg/ml isolated rabbit IgG (Sigma) for 1 h at 37°C, followed by incubation with goat anti-rabbit Alexa 568 antibody (Invitrogen). Cells were counterstained with DAPI (4′,6′-diamidino-2-phenylindole) and imaged on a fluorescence microscope (Zeiss).

Phagocytosis assay. Polymorphonuclear leukocytes (PMNs) (2 × 10⁶) were stimulated with PMA in RPMI with 2% FBS and then infected at an MOI of 10 with the nonopsonized log-phase WT or Δscl mutant strain transformed with a plasmid encoding GFP. Cells were incubated for 20 min in the presence or absence of 10 μg/ml clyt D and then incubated for 10 min with 100 U/ml penicillin and 100 μg/ml streptomycin to kill extracellular bacteria. Cells were washed three times with PBS, fixed with 4% paraformaldehyde, and analyzed by flow cytometry. Neutrophils were gated by side and forward scatter, and the fluorescence intensity was measured for a total of 10,000 cells. Uninfected PMNs were used as a negative control. Flow cytometry data were analyzed with FlowJo v. 9.4.10 (Tree Star, Inc.). To visualize extracellular bacteria by fluorescence microscopy, nonpermeabilized cells were incubated with 0.01 mg/ml isolated rabbit IgG (Sigma) for 1 h at 37°C, followed by incubation with goat anti-rabbit Alexa 568 antibody (Invitrogen). Cells were counterstained with DAPI (4′,6′-diamidino-2-phenylindole) and imaged on a fluorescence microscope (Zeiss).

NET killing and induction experiments. NET killing assays were performed as previously described (35). Briefly, neutrophils were stimulated with 25 nM PMA for 4 h, washed to remove remaining cells, and infected with log-phase bacteria at an MOI of 0.1 for 20 min. As a control, NETs were degraded by the addition of 500 μM mitoracal nuclease (MNase) (Sigma) prior to infection. CFU were enumerated by plating onto THA. Survival was calculated as the percentage of the initial inoculum, and results were compared with those for the wild-type strain to account for donor-dependent variability.

NET induction assays were performed as previously described (35). Briefly, 2 × 10⁶ neutrophils were seeded per well into a 96-well plate and infected with log-phase bacteria at an MOI of 1. Control PMNs were stimulated with 25 nM PMA (positive control) or untreated (negative control). Cells were incubated for 3 h at 37°C, centrifuged, and washed to remove cells, and NET DNA was collected in medium containing 500 μM/ml MNase for 10 min to release NETs from the wells, followed by inactivation of MNase with 5 mM EDTA. The supernatant was incubated with Quant-IT PicoGreen reagent (Invitrogen) for 5 min at room temperature (RT), and fluorescence was quantified on a SpectraMax M3 plate reader at 480-nm excitation and 520-nm emission wavelengths using SoftMax Pro software.

LL-37 and CRAMP susceptibility. Bacteria were grown in RPMI plus 5% TBB to log phase, adjusted to 2 × 10⁵ CFU/ml in RPMI plus 5% TBB, and incubated with 8 μM murine-derived CRAMP or 4 μM human-derived LL-37 (AnaSpec). Samples were taken every 30 min for 120 min, and the CFU were enumerated from THA plates. Survival was calculated as the percentage of the initial inoculum.

FITC-labeled poly-l-lysine and TAMRA-labeled LL-37 binding assay. For poly-l-lysine binding, bacteria were grown to log phase, washed twice with 20 mM HEPES (pH 7.24), and adjusted to 2 × 10⁶ CFU/ml.
Fluorescein isothiocyanate (FITC)-labeled poly-L-lysine (Sigma) was added at 100 μg/ml and incubated for 30 min at 37°C with shaking in the dark. For 6-carboxytetramethylrhodamine (TAMRA)-labeled LL-37 (AnaSpec) with rotation at 37°C in the dark for 30 min. Following incubation with FITC–poly-L-lysine or TAMRA–LL-37, bacteria were washed three times with PBS and analyzed by flow cytometry. Bacteria were gated by side and forward scatters, and the fluorescence intensity was measured for total of 10,000 cells. Unlabeled bacteria were used as a negative control. Flow cytometry data were analyzed by FlowJo v. 9.4.10 (Tree Star, Inc.).

**Peroxide production assays.** THP-1 cells were seeded in 96-well plates at 2 × 10^4 cells with 10 mM PMA 1 day prior to infection. Cells were washed and incubated in medium containing 50 μM Amplex Red (Invitrogen) and 0.1 U/ml horseradish peroxidase (Invitrogen). Flow cytometry data were analyzed with FlowJo v. 9.4.10 (Tree Star, Inc.). Neutrophils were infected with bacteria at an MOI of 1 as described above. Myeloperoxidase (MPO) release into the supernatant was quantified by incubating cell-free supernatant with developing reagent containing 0.5% hexadecyl trimethyl ammonium bromide (Sigma), 0.167 mg/ml o-dianisidine dihydrochloride (Sigma), and 100 μM hydrogen peroxide in 50 mM sodium phosphate buffer (pH 6.0) at RT for 10 min. Total neutrophil MPO content was measured from unstimulated neutrophils lysed with 0.025% Triton X-100. The absorbance was measured using SpectraMax M3 plate reader at 450 nm for MPO using SoftMax Pro software.

**Statistical analysis.** All data were collected from at least three independent experiments in triplicate. Experiments using neutrophils were performed with a minimum of three different healthy volunteers. The data were combined, normalized, and expressed as mean ± standard error of the mean (SEM) except where indicated. All assay data were analyzed by one-way analysis of variance (ANOVA) with Tukey’s multiple comparison posttest or by two-way ANOVA with the Bonferroni posttest. All statistical tests were performed using GraphPad Prism version 5.0 (GraphPad Software Inc.). P values of <0.05 were considered statistically significant.

**RESULTS**

Scl-1 is an LP(X)TG motif protein anchored to the GAS cell wall, and in studies utilizing recombinant protein, Scl-1 has been shown to interact with extracellular matrix proteins and host cells (15, 18–20). We first tested whether Scl-1 contributed to M1T1 GAS virulence using a mouse model of localized subcutaneous infection. Animals were infected with either WT or Δscl mutant bacteria in opposing flanks, and lesion sizes were monitored over a 3-day time course (Fig. 1A and B). Infection with the WT strain produced larger lesions at every time point postinfection than infection with the Δscl mutant (Fig. 1A and B). Furthermore, a higher bacterial load was recovered from the larger WT-infected lesions at 3 days postinfection compared than from Δscl-infected lesions (Fig. 1C). Similar findings in a skin infection model have been previously observed for a different M1 strain (15). To determine whether our in vivo findings resulted from Scl-1-mediated differences in cellular adhesion and invasion, we performed in vitro assays with a human keratinocyte cell line (HaCaT), but we identified no difference among our bacterial strains in either adhesion (Fig. 1D) or invasion (Fig. 1E) of HaCaT keratinocytes. These results suggested that the differences in lesion size and bacterial recovery in our mouse subcutaneous infection model (Fig. 1A and B) were less likely to reflect differences in cell attachment or entry but rather involve a role for Scl-1 in GAS resistance to host innate immune clearance.

**Scl-1 protects bacteria from killing by phagocytic cells.** Neutrophils are the predominant innate immune cell type that migrates to the site of infection to combat invading pathogens. Resident macrophages also play an important role in sensing and destroying pathogens. To determine whether the reduced persistence of the Δscl mutant strain observed in the mouse infection model was due to increased susceptibility to phagocytic cell killing, we studied the contribution of Scl-1 to bacterial survival in total killing assays with human and murine phagocytic cells in vitro. When incubated with isolated human neutrophils (polymorphonuclear cells [PMNs]), Δscl mutant bacteria were more susceptible to killing than either the WT or complemented strain (Fig. 2A). We observed similar trends when we expanded our studies to other phagocytic cell types, including cultured human monocytes (THP-1 cells) (Fig. 2B), murine bone marrow-derived macrophages (Fig. 2C), and cultured murine macrophages (J774 cells, Fig. 2D). Scl-1 was also important for survival in freshly isolated human whole blood (see Fig. 2 in the supplemental material), though the differences between the WT and Δscl mutant strains were not statistically significant in the context of the complemented strain, which survived extremely well in blood (see Fig. 2S in the supplemental material). These data support our hypothesis that the reduced persistence and virulence of the Δscl mutant strain observed in our in vivo infection model (Fig. 1) were due to reduced resistance to phagocytic cell killing.

**Scl-1 protects bacteria from a neutrophil extracellular killing mechanism.** Because Scl-1 is a surface protein, a potential immune evasion function it could serve is to act as an inhibitor of phagocytosis, either by sterically hindering phagocytic cell receptors or by coating molecules that would otherwise be recognized by phagocytic receptors. To study phagocytosis, we introduced a green fluorescent protein (GFP) expression construct into the WT and Δscl M1T1 GAS strains and analyzed neutrophil phagocytosis of the fluorescent bacteria by flow cytometry (Fig. 3A, top panel). To prevent the possibility of serum proteins binding to Scl-1 (21, 22, 25–27) and affecting phagocytosis, bacteria were not preop-
sonized or incubated in the presence of human serum during phagocytosis assays or subsequent in vitro cell-based assays. Control treatment of the neutrophils with cytoD to prevent phagocytosis effectively eliminated the fluorescent signal and validated our assay specificity (Fig. 3A, bottom panel). We found no measurable differences in uptake of the WT strain compared to the \( \Delta scl \) mutant strain by human neutrophils (Fig. 3A and B). These findings were confirmed by fluorescence microscopy and direct visualization of neutrophils infected with GFP-expressing strains (Fig. 3C). Furthermore, when phagocytosis was pharmacologically inhibited by cytoD in the in vitro cell killing experiments, a significant difference in survival of the \( \Delta scl \) strain was still detected (Fig. 3D). Thus, Scl-1 does not appear to function as an antiphagocytic molecule. Furthermore, because the survival of strains in the presence of cytoD-treated cells was not significantly different from the survival of strains incubated with vehicle-treated cells (Fig. 3D), the results further suggest that Scl-1 protects the bacteria from an extracellular killing mechanism of phagocytic cells.

Scl-1 protects against NET-mediated killing and antimicrobial peptides. NETs are a relatively recently discovered killing strategy of neutrophils (36) and are one mechanism by which neutrophils can kill bacteria extracellularly even in the presence of cytoD (37). To determine whether Scl-1 provided protection against NET-mediated killing, we performed pure NET killing assays. PMA was used to stimulate maximum NET production, and bacterial strains were incubated with a cell-free accumulation of NETs. Induced NETs were able to eliminate the \( \Delta scl \) mutant strain more efficiently than its WT parent strain (Fig. 4A). Control treatments with micrococcal nuclease (MNase), an exonuclease derived from \textit{Staphylococcus aureus} that was used to dismantle the DNA backbone, confirmed that intact NET structures were required for the observed differences in WT compared to \( \Delta scl \) mutant bacterial survival (Fig. 4A).

NETs contain many bactericidal components, including antimicrobial peptides, granule proteases, and histones (38). The human cathelicidin antimicrobial peptide LL-37 is a major component of NETs and contributes to GAS killing (37, 38). Incubation of the strains with recombinant LL-37 in vitro demonstrated that the presence of Scl-1 delayed the killing kinetics of the WT and complemented strains compared with the \( \Delta scl \) mutant strain (Fig. 4B). These data support that it may specifically be the LL-37 found in NETs that is responsible for the more effective elimination of the \( \Delta scl \) strain (Fig. 4A). LL-37 is a cationic molecule that exerts its bactericidal activity through pore formation initiated upon LL-37 binding to negatively charged bacterial surfaces (39). Bacterial binding studies with positively charged FITC-labeled poly-L-lysine demonstrated that the presence of Scl-1 reduces the binding of positively charged molecules to the bacteria (Fig. 4C). Binding studies with TAMRA-labeled LL-37 (Fig. 4D) corroborated this observation and support a mechanism in which increased LL-37 binding to the mutant bacterial cell surface contributes to the accelerated killing kinetics seen in Fig. 4B.

The murine cathelicidin-related antimicrobial peptide (CRAMP) similarly localizes to murine phagocyte extracellular...
traps (40, 41). To expand on our data examining the sensitivity of our mutant strain to antimicrobial peptides in extracellular traps, we used macrophages isolated from mice genetically deficient in CRAMP in bacterial killing experiments. In contrast to experiments performed with macrophages isolated from WT mice (Fig. 2C), we observed that the survival of the Δscl mutant was equivalent to that of Scl-1-expressing strains when incubated with CRAMP-deficient macrophages (Fig. 4E). Similarly, Scl-1 conferred slower killing kinetics by recombinant CRAMP in vitro (Fig. 4F). Thus, our data show that reducing binding and susceptibility to cathelicidin antimicrobial peptides in the Scl-1-expressing WT M1T1 strain may contribute to its resistance to phagocyte extracellular trap-mediated killing.

Scl-1 suppresses MPO activity and subsequent NET formation. Previous research by our lab has demonstrated that the immunodominant GAS surface protein virulence factor M1 increases bacterial survival in NETs by capturing LL-37 but simultaneously binds fibrinogen in proinflammatory complexes to activate neutrophils and generate NETs (37, 42). We asked whether the Scl-1-dependent differences in phagocyte survival (Fig. 2) were influenced not only by relative susceptibility to antimicrobial LL-37 found in NETs (Fig. 4) but also modulation of the abundance of NETs formed. Indeed, we found that the Δscl mutant strain induced the formation of significantly more NETs, indicating that in the WT and complemented strains, Scl-1 appears to suppress NET formation (Fig. 5A).

The production of reactive oxygen species (ROS) through the oxidative burst is a critical stimulatory pathway promoting the generation of NETs (3). When neutrophils were treated with a general oxidative burst inhibitor (butylated hydroxyanisole [BHA]) or when catalase, a peroxide-degrading enzyme, was included in neutrophil killing experiments, differences in strain survival were abolished, compared to the enhanced survival of the WT over the Δscl mutant seen under control conditions (Fig. 5B and C). However, when we examined the production of the ROS hydrogen peroxide by cells in response to the different strains, we found no differences in the amount of oxidants produced (Fig. 5D). Thus, limiting NET formation via inhibition of the oxidative burst response generally decreases the ability of the cells to kill the Δscl strain, but Scl-1 does not aid in suppressing the generation of ROS.

Following ROS exposure, granule and nuclear membranes break down and initiate the mixing of granule contents with the nucleus and begin the NET formation process (3). Myeloperoxidase (MPO) is a major enzyme stored in neutrophil azurophilic granules, and release of MPO into the environment and subsequent localization to NETs are a hallmark of NET formation (38). Therefore, we measured the release of MPO from neutrophils in response to the different strains as a gauge of NET generation. After 90 min of infection and over a 45-min time course, the Δscl mutant strain induced greater release of MPO by neutrophils into the medium (Fig. 5E), supporting that Scl-1 in the WT and complemented strains prevents NET induction (Fig. 5A) by inhibiting MPO release. Indeed, when MPO activity was blocked using the pharmacological agent 4-aminobenzoic acid hydrazide (ABAH), we abrogated the protective function of Scl-1 in bacterial resistance to neutrophil killing (Fig. 5F). Based on these findings, we conclude that Scl-1 blunts the release of MPO and that Scl-1 not...
only can directly protect bacteria from the cathelicidin LL-37 deployed in NETs (Fig. 4) but also suppresses the quantity of NETs produced (Fig. 5).

**DISCUSSION**

Surface proteins of GAS are critical mediators of bacterial resistance to host innate immunity. A particularly well-characterized example is M protein, which mediates adhesion to host cells, provides resistance to opsonophagocytosis, and improves survival in NETs (2, 43). The multiple roles that M protein plays in immune resistance are likely to contribute to the increased virulence in subcutaneous mouse models of infection and in human blood (2, 43). Similarly, Scl-1 in other GAS serotypes has been reported to be important for host cell adhesion and survival in blood and serum (15, 19–22, 25, 27). The hypervariable N-terminal domain of the Scl-1 protein is largely responsible for binding various serum proteins, while the collagen-like domain has been shown to bind integrins to facilitate interactions with host cells (15, 19–22, 25, 27). Collagen-like proteins in other pathogenic bacteria, including *Streptococcus pneumoniae* (44), *Bacillus anthracis* (45), and *Legionella pneumophila* (46), similarly aid in bacterial adhesion to and invasion of host cells. In our studies of the Scl-1 protein in the physiological context of the predominant M1T1 GAS clone, we found that Scl-1 was not important for adhesion to keratinocytes, nor did it affect phagocytosis of bacteria in the absence of serum proteins, but rather it represented an important virulence determinant *in vitro* and *in vivo* by increasing resistance to phagocyte killing mechanisms. With neutrophils, a critical innate immune cell, Scl-1 appeared to both limit the formation of NETs and provide resistance to cathelicidins found within the NETs. These resistance mechanisms can be exclusively attributed to Scl-1 of M1T1 GAS, as there are no differences in other surface molecules of our bacterial strains (see Fig. S1 in the supplemental material). Furthermore, the role of Scl-1 in immune resistance is likely due to the N-terminal domain of M1 serotype Scl-1, as the
collagen-like domain appears to chiefly play a role in bacterial adhesion to host cells (19, 20). Sequence analysis of the N-terminal domain of M1 Scl-1 did not reveal significant homology to other proteins of known function (data not shown). Although many studies of Scl-1 in non-M1 GAS strains have not previously demonstrated a role for the protein in phagocyte resistance (15, 19–22, 25, 27), a recent study similarly described a role for Scl-1 in a non-M1 strain in whole-blood survival and neutrophil resistance (13), consistent with our observations of M1T1 GAS with neutrophils and multiple macrophage cell lines (Fig. 2) and whole blood (see Fig. S2 in the supplemental material). Another interesting recent study suggests that Scl-1 could also be important for GAS persistence and delayed wound healing (16). We hypothesize that the larger skin lesions induced by WT Scl-1-expressing M1T1 GAS in vivo (Fig. 1) could reflect a combined result of resistance to phagocytic killing at the site of infection and interference with the wound healing process. This may also explain the different outcomes observed in previous mouse infection studies, where strains lacking Scl-1 resulted in differences in skin infection but not systemic infection (data not shown) (15).

We found that Scl-1 in M1T1 serotype GAS confers resistance to NET-mediated killing, which may be in large part due to the antimicrobial peptides found within the NETs (Fig. 4). Although we have focused our studies primarily on extracellular traps generated by neutrophils, extracellular traps can be generated by a number of innate immune cell types (38), including macrophages (40, 41). Thus, our findings can be extended to the other phagocytic cell types used in our studies (Fig. 2 and 4), though susceptibility of the mutant strain to antimicrobial peptides in these experiments may not necessarily be limited to those found in extracellular traps. Susceptibility of the mutant strain to extracellular trap antimicrobial peptides may in part be explained by altered surface charge (Fig. 4). In addition to Scl-1, other surface proteins of GAS, such as the surface protein M1 in the GAS M1T1 clone, similarly promote survival against NET-mediated killing by conferring protection from cathelicidin (37).

Our data further show that Scl-1 has an additional role in suppressing the release of MPO, which ultimately limits the production of NETs (Fig. 5). A similar effect is observed in GBS infections, where engagement of the immunosuppressive receptor Siglec-9 by surface glycans results in decreased NET formation and increased bacterial survival in NETs (47). Scl-1 likely does not engage an immunosuppressive receptor, as the phagocytosis of the strains (Fig. 3) and the oxidative burst response (Fig. 5) are intact in cells infected with Scl-1-expressing strains. However, the exact molecular mechanism by which Scl-1 prevents MPO release remains to be elucidated and warrants further study. Thus, Scl-1 appears to have a multifunctional role in providing protection from extracellular traps and antimicrobial peptides while simultaneously suppressing release of azurophilic granule contents and limiting extracellular trap formation. The diverse effects of Scl-1 are difficult to explain and will be explored in future work.

As Scl-1 is an important virulence factor for the prevalent M1T1 clone of GAS, it may prove to be an effective therapeutic target. A study by Åkesson and colleagues demonstrated that pa-
tients with invasive GAS infection have significantly lower levels of antibodies against Scl-1 than patients with mild infections (48). This study suggests that the production of anti-Scl-1 antibodies is important for the outcome of invasive GAS infections (48). Because our data suggest that the hypervariable N-terminal domain of M1T1 Scl-1 is responsible for phagocyte resistance, this portion of the protein may prove to be a useful target for vaccine development, circumventing the possibility of cross-reactivity with human collagen. A multivalent strategy to target the hypervariable region of M1T1 Scl-1, similar to the approach applied to the development of an M protein vaccine (49), can be promising for the development of a GAS-specific therapeutic vaccine. This strategy of designing a therapeutic for a specific bacterial virulence factor is particularly attractive in the face of rapidly growing numbers of antibiotic-resistant bacteria.

ACKNOWLEDGMENTS

Support for this work was provided National Institutes of Health grants AI077780 and AR052728 to V.N., UCSD/SDSU IRACDA Postdoctoral Fellowship Program grant GM068524 to C.Y.M.O., a grant from the Technische Universität Braunschweig Fellowship Program grant GM068524 to C.Y.M.O., a grant from the Undergraduate Research Center of Occidental College to N.E., H.N., and J.S. We gratefully acknowledge Magnus Rasmussen, Jason Cole, and the lab of Roberta Pollock for the use of several reagents and protocols.

REFERENCES


